Researchers unveiled a prognostic nomogram designed for children with aplastic anemia (AA) treated with cyclosporine monotherapy, aiming to address the unpredictable response to treatment. The model targets early outcome prediction for pediatric patients, a persistent clinical challenge in managing this rare, life-threatening bone marrow failure condition. The headline development is practical: a cyclosporine-monotherapy–specific tool intended to stratify patients sooner, potentially guiding intensity of follow-up and earlier decision-making around therapy escalation. As pediatric AA care lacks universally standardized prognostic frameworks, the addition of a tailored nomogram could support more consistent clinical trial design as well as day-to-day practice decisions.